Long-term survival of a patient with stage IV pulmonary large cell carcinoma achieved by combined-modality therapy: Report of a case

Surgery Today

Volumn 30, Issue 6, 2000, Pages 561-566

  Kobayashi, Shunsuke ^a   Okada, Shinichiro ^a   Hasumi, Toru ^b   Sato, Nobuyuki ^b   Fujimura, Shigefumi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b SENDAI KOUSEI HOSPITAL   (Japan)

Author keywords

Combined modality therapy; Drug screening assay; Heterogeneity; Lung cancer; Tissue culture

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASE REPORT; HUMAN; LARGE CELL CARCINOMA; MALE;

EID: 0033938584     PISSN: 09411291     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005950070130     Document Type: Article

References (15)

1. 1. Von-Hoff DD, Clark GM, Forseth BJ, Cowan JD (1986) Simultaneous in vitro drug sensitivity testing on tumors from different sites in the same patient. Cancer 58:1007-1013
2. 2. Rofstad EK, Zaffaroni N, Hystad ME (1990) Heterogeneous radiation and heat sensitivity in vitro of human melanoma xenograft lines established from different lesions in the same patient. Comparisons with the radiation and heat sensitivity of cells isolated from the donor patient's surgical specimens. Int J Radiat Biol 57:1113-1122
3. 3. Kobayashi S, Inaba H, Okada S, Nakada T (1989) Culture and changes in dynamics of proliferation of pulmonary small cell carcinoma cells. Tohoku J Exp Med 159:1-14
4. 4. Kobayashi S, Fujimura S (1992) Characterization and the clinical application of cultured human pulmonary carcinoma cells. Tohoku J Exp Med 168:375-386
5. 5. Kobayashi S, Okada S, Hasumi T, Sato N, Fujimura S (1998) Modulating activity of indomethacin to vincristine cytotoxicity in various human carcinoma cells. Tohoku J Exp Med 186:313-322
6. 6. Broder LE, Sridhar KS, Selawry OS, Charyulu KN, Rao RK, Saldana MJ, Donnelly EJ, Raub WA Jr (1994) A randomized clinical trial in bronchogenic small-cell carcinoma evaluating alternating maintenance therapy of vincristine, adriamycin, procarbazine, and etoposide (VAPE) with cyclophosphamide, CCNU, and methotrexate (CCM) versus CCM maintenance alone in complete responders following VAPE induction and late intensification. Am J Clin Oncol 17:527-537
7. 7. Sirzea F, Westberg R, Lewensohn R, Billing B (1994) Dose intensity of the CAVE regimen in small cell lung cancer correlates to response rate. Lung Cancer 11:393-400
8. 8. Lorigan P, Lee SM, Betticher D, Woodhead M, Weir D, Hanley S (1995) Chemotherapy with vincristine/ifosfamide/carboplatin/ etoposide in small cell lung cancer. Semin Oncol 22:32S-41S
9. 9. Sehested M, Hirsch FR, Osterlind K, Olsen AJE (1986) Morphologic variations of small cell lung cancer. Cancer 57:804-807
10. 10. Fushimi H, Kikui M, Morino H, Yamamoto S, Tateishi R, Wada A, Aozasa K, Kotoh K (1996) Histologic changes in small cell lung carcinoma after treatment. Cancer 77:278-283
11. 11. Markesbery WR, Brooks WH, Gupta GD (1978) Treatment for patients with cerebral metastases. Arch Neurol 35:754-756
12. 12. Gelber RD, Larson M, Borgelt BB, Kramer S (1981) Equivalence of radiation schedules for the palliative treatment of brain metastasis in patients with favorable prognosis. Cancer 48:1749-1753
13. 13. Shahidi H, Kvale PA (1996) Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest 109:271-276
14. 14. Mussi A, Pistolesi M, Lucchi M, Janni A, Chella A, Parenti G, Rossi G, Angeletti CA (1996) Resection of single brain metastasis in non-small-cell lung cancer: prognostic factors. J Thorac Cardiovasc Surg 112:146-153
15. 15. Fry WA, Menck HR, Winchester DP (1996) The national cancer data base report on lung cancer. Cancer 77:1947-1955